Suzhou Kintor Pharmaceutical Inc,   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Suzhou China (2009)

Organization Overview

First Clinical Trial
2016
NCT02826772
First Marketed Drug
2018
metoprolol (lopressor)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Suzhou Kintor Pharmaceutical Inc, | Suzhou Kintor Pharmaceuticals,inc | Suzhou Kintor Pharmaceuticals,inc. | Suzhou Kintor Pharmaceuticals Inc | Suzhou Kintor Pharmaceuticals Inc. | VISUM PHARM

Active Ingredients

Marketed Drugs (1)

metoprolol (lopressor) (2018)

Drugs in Phase 3 Trials (1)

proxalutamide (6 trials)

Drugs in Phase 2 Trials (5)

ascrinvacumab (1 trial)

gt90001 (2 trials)

kn046 (1 trial)

kx- 826 (1 trial)

nivolumab (opdivo) (2 trials)

Drugs in Phase 1 Trials (2)

gt20029 (1 trial)

kx0826 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alopecia (Phase 1)

Alopecia Areata (Phase 1)

Breast Neoplasms (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 8